CD8A and type 1 diabetes mellitus: In type 1 diabetic patients, treatment with an anti-CD3 mAb has been shown to induce CD8+CD25+ Tregs, which express cytotoxic T-lymphocyte-associated protein (CTLA-4) and Foxp3 to facilitate the inhibition of CD4+ T cells in response to therapy [65].